TANDEM DIABETES CARE INC (TNDM) Stock
TNDM has an Alpha Score of 20 out of 100 (poor), computed on Nov 4, 2026 from 2 of 4 sub-scores. 4 members of Congress disclosed 8 trades in TNDM since 2015: 5 purchases and 3 sales, most recently Gilbert Cisneros (purchase, Sep 29, 2026). 5 of the hedge funds AlphaScala tracks reported TNDM in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Citadel's at $26.19M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 9, 2026.
What is TNDM's Alpha Score?
How it works →Alpha Score of 20 reflects poor overall profile with weak momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded TANDEM DIABETES CARE INC (TNDM)?
Most recent: Gilbert Cisneros (purchase, Sep 29, 2026); records start May 27, 2015.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-09-29 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-03 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2025-09-22 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2025-03-19 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-03-04 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-08-05 | purchase | $1k – $15k |
| Dan Goldman D-NY · House | 2023-07-12 | sale | $1k – $15k |
| Tom MacArthur R-NJ · House | 2015-05-27 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 6, 2026.
See all TNDM political trades →Which hedge funds own TNDM?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.74M | $26.19M | -21% |
| Millennium Management Israel Englander | 1.31M | $19.79M | +72% |
| D.E. Shaw David Shaw | 682K | $10.29M | -13% |
| Point72 Steve Cohen | 611K | $9.22M | +45% |
| Hussman Investment Trust John Hussman | 168K | $2.74M | NEW |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are TANDEM DIABETES CARE INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 27, 26 | Twomey Christopher J | Director | SELL | 1.7K | $33K |
SEC Form 4 filings as of Nov 9, 2026
See cluster-buy signals across all tickers →What are TNDM's key statistics?
Key statistics as of Nov 4, 2026
How does TNDM's valuation compare with the Healthcare sector?
| Metric | TNDM | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -6.08% | 3.62% | 174 |
| Return on equity | -45.97% | 2.96% | 200 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 10, 2026). P/E excludes loss-making companies.
TNDM price chart
Powered by TradingViewWhat does TANDEM DIABETES CARE INC do?
Tandem Diabetes Care designs, develops, and commercializes advanced technology solutions for insulin-dependent diabetes management worldwide. The company's flagship products are the t:slim X2 insulin pump and the Tandem Mobi automated insulin delivery system, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology that helps optimize blood glucose levels. These durable insulin pumps work alongside continuous glucose monitoring systems, including integration with Abbott's FreeStyle Libre 3 Plus sensor. Tandem also manufactures disposable products such as infusion sets and cartridges for insulin storage and delivery. Nearly three-quarters of revenue derives from the United States, with the remainder primarily from other developed nations. The company serves individual patients with insulin-dependent diabetes across multiple distribution channels, including direct sales, pharmacy partnerships, and healthcare providers. Founded in 2006 and headquartered in San Diego, California, Tandem operates as a global leader in automated insulin delivery technology.